Affordable Biologics: Patent Limits for Drug Manufacturers
This new law aims to make affordable biological drugs more accessible. It limits the number of patents that original drug manufacturers can use in lawsuits against companies introducing cheaper generic versions. This could lead to lower prices for important medications for citizens in the future.
Key points
Limits the number of patents that original drug manufacturers can assert in patent infringement lawsuits, aiming to accelerate the introduction of more affordable generic alternatives.
The changes apply to applications for biological product approval submitted after the law's enactment, meaning patient benefits will emerge over time.
Status:
Placed on Calendar
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens
(explained here).
Start recording it now.